1. Home
  2. OCX vs IRD Comparison

OCX vs IRD Comparison

Compare OCX & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCX
  • IRD
  • Stock Information
  • Founded
  • OCX 2009
  • IRD 2018
  • Country
  • OCX United States
  • IRD United States
  • Employees
  • OCX N/A
  • IRD N/A
  • Industry
  • OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • IRD
  • Sector
  • OCX Health Care
  • IRD
  • Exchange
  • OCX Nasdaq
  • IRD NYSE
  • Market Cap
  • OCX 35.1M
  • IRD 36.1M
  • IPO Year
  • OCX N/A
  • IRD N/A
  • Fundamental
  • Price
  • OCX $2.01
  • IRD $1.15
  • Analyst Decision
  • OCX Buy
  • IRD Strong Buy
  • Analyst Count
  • OCX 3
  • IRD 1
  • Target Price
  • OCX $4.42
  • IRD $8.00
  • AVG Volume (30 Days)
  • OCX 53.0K
  • IRD 154.1K
  • Earning Date
  • OCX 11-12-2024
  • IRD 02-19-2025
  • Dividend Yield
  • OCX N/A
  • IRD N/A
  • EPS Growth
  • OCX N/A
  • IRD N/A
  • EPS
  • OCX N/A
  • IRD N/A
  • Revenue
  • OCX $709,000.00
  • IRD $8,381,000.00
  • Revenue This Year
  • OCX N/A
  • IRD N/A
  • Revenue Next Year
  • OCX $106.34
  • IRD $29.37
  • P/E Ratio
  • OCX N/A
  • IRD N/A
  • Revenue Growth
  • OCX N/A
  • IRD N/A
  • 52 Week Low
  • OCX $1.92
  • IRD $0.81
  • 52 Week High
  • OCX $3.48
  • IRD $2.77
  • Technical
  • Relative Strength Index (RSI)
  • OCX 42.58
  • IRD N/A
  • Support Level
  • OCX $1.99
  • IRD N/A
  • Resistance Level
  • OCX $2.30
  • IRD N/A
  • Average True Range (ATR)
  • OCX 0.12
  • IRD 0.00
  • MACD
  • OCX 0.02
  • IRD 0.00
  • Stochastic Oscillator
  • OCX 25.70
  • IRD 0.00

About OCX Oncocyte Corporation

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: